Running a rare disease trial breaks most of the assumptions that govern conventional clinical research. The patient population may number in the hundreds worldwide, scattered across many countries. There may be no established endpoints, no natural history data, and no experienced investigators. Enrollment can take years. Choosing a CRO that genuinely understands these realities, rather than one applying a standard playbook, is often the difference between a trial that completes and one that stalls. Here is a guide to the CROs best suited to rare disease and how to select one.
Why rare disease trials are uniquely hard
The core challenge is scarcity. Patients are few and dispersed, which means recruitment depends on finding people across many countries and often working with patient advocacy groups who know where they are. Sites are inexperienced, since few investigators have run trials in an ultra-rare condition, so much of the work is enabling and supporting sites rather than simply selecting them. Endpoints may not exist, requiring novel or bespoke measures and careful regulatory negotiation. Natural history is often poorly understood, which complicates trial design and interpretation. And every patient matters enormously, so retention and the patient experience are not soft concerns but operational imperatives. A CRO that treats a rare disease trial like a scaled-down conventional study will struggle.
The CROs with real rare disease capability
Several types of provider serve this space well.
- Global CROs with dedicated rare disease groups, including IQVIA, ICON, Parexel, and Thermo Fisher’s PPD, bring multinational reach, which matters when your patients are spread across a dozen countries, along with the regulatory experience to navigate orphan pathways.
- Medpace is frequently chosen by small and mid-sized sponsors for its full-service model and senior therapeutic involvement, which suits the hands-on nature of rare disease work.
- Rare-disease-focused specialists bring concentrated expertise, deep relationships with patient advocacy organizations and the small community of expert investigators, and operational models built around tiny, dispersed populations rather than adapted from large trials.
For many rare disease sponsors, the specialist advantage, particularly the advocacy relationships and the experience of building a trial around a handful of patients, outweighs the infrastructure advantage of the giants.
What actually matters in the selection
A few capabilities genuinely predict success in rare disease. Patient identification and advocacy relationships may be the single most important, because in a condition affecting a few hundred people worldwide, the patient organizations often know the families and the treating physicians, and a CRO with genuine standing in that community can find patients others cannot. Global reach with local capability matters, since you may need to run in many countries to find enough participants. Regulatory expertise in orphan pathways, including the designations and the flexible approaches regulators may accept for tiny populations, is essential. Site enablement, the ability to support inexperienced sites so they can execute well, is a core skill. And flexibility matters more than process rigor, because rare disease trials rarely go to plan and a partner who can adapt is worth far more than one who cannot.
Questions worth asking
Ask specifically about their experience in your disease or a comparable ultra-rare condition, not rare disease in general. Ask how they will find patients, and press for concrete strategies rather than reassurance, since this is the crux. Ask about their relationships with relevant patient advocacy organizations. Ask how they support inexperienced sites. Ask about their orphan regulatory experience. And ask who will actually staff your trial and how senior they are, because rare disease work demands judgment and adaptability, not just process execution.
The bottom line
Rare disease trials succeed or fail on patient identification, site enablement, regulatory creativity, and flexibility, not on the scale of the CRO you hire. The global CROs bring multinational reach and orphan regulatory experience, while rare-disease specialists bring advocacy relationships and operational models genuinely built for tiny, dispersed populations. Choose the partner whose experience most closely matches your specific condition and whose approach to finding and keeping your handful of patients is concrete rather than aspirational, because in rare disease, that is the whole ballgame.
Design the trial around the patients you can actually reach
The deepest lesson in rare disease research is that trial design and operational reality cannot be separated, because a beautifully designed study that cannot enroll is worthless. This means the design itself should be shaped by where your patients actually are and what they can realistically do. If your patients are scattered across many countries and travel is burdensome, decentralized and hybrid approaches, remote visits, home health, and local laboratory work, may be the difference between a trial that completes and one that stalls, and a CRO experienced in those models becomes essential. If there is no established endpoint, you may need to develop and validate one, which requires regulatory engagement early and a partner who has navigated that conversation before. If natural history is poorly understood, you may need to build that understanding, sometimes through a registry or a natural history study that also serves to identify and engage patients ahead of the interventional trial, a strategy that experienced rare disease teams use deliberately. And because every patient matters so much, the patient and family experience is an operational priority: burdensome protocols cause dropouts you cannot afford, and a partner who thinks carefully about reducing burden protects your study’s integrity. The practical takeaway is to involve your CRO and your regulatory advisors in the design conversation early, before the protocol is fixed, so that operational reality shapes the science rather than colliding with it later. In rare disease more than anywhere else, the trial you can actually run is the only trial worth designing.
Where to look for candidates
Finding CROs with genuine rare disease depth takes deliberate searching, since the capability is not evenly distributed and the marketing rarely distinguishes real experience from aspiration. Industry directories let you identify providers by therapeutic focus, and patient advocacy organizations in your disease area are often an excellent and underused source of intelligence about which CROs and investigators genuinely understand the condition. Speak to other sponsors who have run trials in comparable rare diseases, since their firsthand experience of who delivered and who did not is worth more than any credential. In a field this specialized, the informal network often knows things no formal search will surface.
Talk to the patient community first
Before you even begin evaluating CROs, talk to the patient advocacy organization for your disease. They frequently know where the patients are, which physicians treat them, what burdens families can and cannot bear, and which sponsors and CROs have treated the community well or badly. That knowledge shapes your protocol, your site strategy, and your CRO selection, and it is available for the asking. In rare disease, the community is small, memories are long, and the goodwill you build or squander travels fast, so beginning there is both good ethics and good operations.
Plan for a longer timeline than you want
Rare disease trials take longer than sponsors plan for, essentially always, because finding a few hundred dispersed patients is genuinely hard and the assumptions built into the original timeline are almost invariably optimistic. Build that reality into your budget, your runway, and your investor communications from the outset. A company that has funded a realistic timeline can be patient and rigorous; a company that has funded an optimistic one ends up cutting corners or running out of money just as enrollment finally gains momentum, which is the most frustrating way imaginable to lose a program.
For the full, maintained list of contract research organizations, filterable by therapeutic focus, browse the BioMed Nexus CRO directory, and see our guides on how to choose a CRO and running decentralized trials, an approach especially valuable when patients are dispersed.
Frequently asked questions
What are the best CROs for rare disease trials?
Global CROs with dedicated rare disease groups, including IQVIA, ICON, Parexel and Thermo Fisher's PPD, offer multinational reach and orphan regulatory experience. Medpace is often chosen by smaller sponsors for senior therapeutic involvement. Rare-disease-focused specialists bring concentrated expertise, patient advocacy relationships, and operational models built for tiny, dispersed populations.
Why are rare disease trials so difficult?
Patients are few and dispersed across many countries, sites are usually inexperienced with the condition, established endpoints often do not exist, natural history data may be poor, and every single patient matters enormously for retention and results. A CRO that treats a rare disease trial like a scaled-down conventional study will struggle with these realities.
What matters most when choosing a rare disease CRO?
Patient identification and relationships with patient advocacy organizations matter most, since advocacy groups often know the families and treating physicians in ultra-rare conditions. Also critical are global reach with local capability, regulatory expertise in orphan pathways, the ability to enable inexperienced sites, and flexibility, since rare disease trials rarely go to plan.
